Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
SD 0006
Cat. No.:
OB0225LY-0418
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
SD 0006 is a MAPK p38 alpha inhibitor.
Synonym:
SD-06; 271576-80-8; 1-(4-(5-(4-Chlorophenyl)-4-(pyrimidin-4-yl)-1H-pyrazol-3-yl)piperidin-1-yl)-2-hydroxyethanone; 1-(4-(5-(4-Chlorophenyl)-4-(pyrimidin-4-yl)-1H-pyrazol-3-yl)piperidin-1-yl)-2-hydroxyethan-1-one; 1-(4-(3-(4-Chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-5-yl)-1-piperidinyl)-2-hydroxyethanone; 5-p-Chlorophenyl-3-[N-(2-hydroxyacetyl)piperidin-4-yl]-4-pyrimidin-4-yl-1H-pyrazole; 1-(4-(3-(4-chlorophenyl)-4-(pyrimidin-4-yl)-1H-pyrazol-5-yl)piperidin-1-yl)-2-hydroxyethan-1-one
CAS No.:
271576-80-8
Compound CID:
9865587
Formula:
C20H20ClN5O2
Formula Weight:
397.86
Specification
Relative Density:
1.367 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
SD 0006 can be used in drug development studies or play an important role in screening for biological activity.
Library Information
Targets:
Kinases
Receptors:
p38 MAPK
Pathways:
Autophagy; MAPK
Plate Number:
AOCL-6
Plate Location:
d4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
29 mg/mL; 72.89 mM
